MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Puma Biotechnology Inc

Closed

SectorHealthcare

3.57 -0.83

Overview

Share price change

24h

Current

Min

3.55

Max

3.6

Key metrics

By Trading Economics

Income

-16M

3M

Sales

-13M

46M

P/E

Sector Avg

4.397

40.527

Profit margin

6.464

Employees

172

EBITDA

-14M

4M

Recommendations

By TipRanks

Recommendations

Sell

12 Months Forecast

-16.2% downside

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

11M

170M

Previous open

4.4

Previous close

3.57

News Sentiment

By Acuity

23%

77%

28 / 375 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

6 lip 2025, 23:55 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustments -- Market Talk

6 lip 2025, 22:35 UTC

Acquisitions, Mergers, Takeovers

South32 Expects to Complete Transaction in Late 2025

6 lip 2025, 22:35 UTC

Acquisitions, Mergers, Takeovers

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

6 lip 2025, 22:34 UTC

Acquisitions, Mergers, Takeovers

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

5 lip 2025, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 lip 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 lip 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 lip 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

4 lip 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 lip 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4 lip 2025, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

4 lip 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

4 lip 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

4 lip 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 lip 2025, 15:57 UTC

Market Talk

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 lip 2025, 15:49 UTC

Market Talk

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 lip 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 lip 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 lip 2025, 15:49 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Received All Required Authorizations

4 lip 2025, 15:48 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 lip 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: Agreement Was Announced on Dec. 19

4 lip 2025, 15:47 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 lip 2025, 15:46 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 lip 2025, 14:30 UTC

Acquisitions, Mergers, Takeovers

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 lip 2025, 13:53 UTC

Market Talk

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 lip 2025, 13:41 UTC

Market Talk

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 lip 2025, 13:41 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

4 lip 2025, 13:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4 lip 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 lip 2025, 12:37 UTC

Market Talk

Fund Manager Roundup: U.S. Treasurys in Focus -2-

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-16.2% downside

12 Months Forecast

Average 3 USD  -16.2%

High 4 USD

Low 2 USD

Based on 2 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

2 ratings

0

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

28 / 375 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.